Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

Delayed Quote. Delayed  - 09/23 05:31:07 pm
79.15 CHF   -0.13%
09/23 NOVARTIS : receives three new FDA approvals for the expanded use of ..
09/23 NOVARTIS : announces positive top-line results from ASCEND-4, a Phas..
09/22 DOES NOVARTIS A : NVS) Have The Solution For Malaria?
News SummaryMost relevantAll newsSector news 

UK Health Body Approves Novartis's Tasigna For CML

share with twitter share with LinkedIn share with facebook
share via e-mail
04/25/2012 | 01:16am CEST

The U.K.'s health-cost regulator has decided to back an expensive cancer drug from Novartis AG (NVS) for treating chronic myeloid leukemia--but not one from U.S.-based Bristol-Myers Squibb Co. (BMY)--after the Swiss drug maker offered to cut the drug's price.

The independent National Institute for Clinical Excellence, known by its acronym NICE, said Wednesday it approved Novartis's Tasigna and the company's older drug, whose brand name is Glivec, for use in treating CML on the publicly funded National Health Service. The generic names for Tasigna and Glivec are nilotinib and imatinib, respectively.

However, NICE said it wasn't approving Bristol-Myers Squibb's Sprycel, also known as dasatinib.

CML is a cancer of blood-forming cells in the bone marrow that usually develops slowly, which is why it is described as a chronic form of the disease.

NICE director Carole Longson said: "The recommendations reaffirm the use of imatinib as an effective treatment for the majority of patients and a cost-effective use of NHS resources, and we are also very pleased to be able to add a further treatment option for these patients by recommending nilotinib.

"Although no trials directly comparing dasatinib and nilotinib were available, the committee concluded from indirect comparisons that dasatinib and nilotinib could be considered equally as effective in treating CML.

"However, the manufacturer of nilotinib has already agreed with the Department of Health to provide the drug to the NHS at a discounted price. This reduction in cost enabled the independent committee to approve nilotinib for use on the NHS."

Dasatinib and nilotinib both cost over GBP30,000 per patient a year and the standard dose of imatinib costs GBP20,000.

NICE didn't disclose the price discount offered by Novartis for nilotinib.

-By Sten Stovall, Dow Jones Newswires; +44 207 842 9292; sten.stovall@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on NOVARTIS AG
09/23 NOVARTIS : receives three new FDA approvals for the expanded use of Ilaris treat..
09/23 NOVARTIS : Alcon Research Assigned Patent
09/23 NOVARTIS : announces positive top-line results from ASCEND-4, a Phase III trial ..
09/22 DOES NOVARTIS AG (NYSE : NVS) Have The Solution For Malaria?
09/22 NOVARTIS : Pharma star celebrates two special anniversaries
09/21 NOVARTIS : Novel Novartis Compound Shows Potential as Effective Therapy for Trea..
09/21 NOVARTIS : Novel Novartis malaria compound shows potential to be effective again..
09/21 NOVARTIS : Federal Contracts Awarded by Federal Agencies in Iowa (Sept. 21)
09/21 NOVARTIS : $256,292 Federal Contract Awarded to Alcon Laboratories
09/21 Emma named as new Glaxo
More news
Sector news : Pharmaceuticals - NEC
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira
09/23 Endo International CEO steps down, Campanelli named successor
09/23DJSHIRE : Files 8K - Direct Or Off-Balance Sheet Financial Obligation
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
09/23 FDA OKs three new uses for Novartis' Ilaris
09/23 Fovista Results Could See Novartis Dig Deep, And Gilead's NASH Data
09/23 BIOTECH FORUM DAILY DIGEST : Can Biotech Broach Resistance Levels? Worst Now Ove..
09/23 Healthcare ratings roundup - new coverage
09/22 Allergan's Second Move Spells Showdown With Intercept And Gilead
Financials ($)
Sales 2016 48 854 M
EBIT 2016 11 519 M
Net income 2016 7 821 M
Debt 2016 14 753 M
Yield 2016 3,47%
P/E ratio 2016 23,89
P/E ratio 2017 21,60
EV / Sales 2016 4,70x
EV / Sales 2017 4,56x
Capitalization 214 744 M
More Financials
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 89,8 $
Spread / Average Target 10%
Consensus details
EPS Revisions
More Estimates Revisions
Joseph Jimenez Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Kirsch Chief Financial Officer
Vasant Narasimhan Chief Medical Officer & Head-Drug Development
Srikant Madhav Datar Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG-8.70%214 744
JOHNSON & JOHNSON15.66%325 050
ROCHE HOLDING LTD.-11.18%218 395
PFIZER INC.6.13%207 809
MERCK & CO., INC.19.20%174 098
More Results